Galera Therapeutics Inc [GRTX] stock is trading at $0.14, down -3.46%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The GRTX shares have gain 12.50% over the last week, with a monthly amount drifted -41.80%, and not seem to be holding up well over a long-time horizon.
On 14, November 2023, Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates. In a post published today on Yahoo Finance, FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued.
From an analyst’s perspective:
Galera Therapeutics Inc [NASDAQ: GRTX] stock has seen the most recent analyst activity on August 10, 2023, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $0.50 from $6.
Galera Therapeutics Inc [GRTX] stock has fluctuated between $0.09 and $3.59 over the past year. Currently, Wall Street analysts expect the stock to reach $0.35 within the next 12 months. Galera Therapeutics Inc [NASDAQ: GRTX] shares were valued at $0.14 at the most recent close of the market. An investor can expect a potential return of 150.0% based on the average GRTX price forecast.
Analyzing the GRTX fundamentals
An extended look at the Principal structure reveals enduring liabilities to the total capital of 457.99 and enduring liabilities to assets of 317.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1281 points at the first support level, and at 0.1167 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1477, and for the 2nd resistance point, it is at 0.1559.
Galera Therapeutics Inc [GRTX] reported earnings per share of -$0.28 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.4/share, meaning a difference of $0.12 and a surprise factor of 30.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.48 per share as compared to estimates of -$0.38 per share, a difference of -$0.1 representing a surprise of -26.30%.
Ratios To Look Out For
For context, Galera Therapeutics Inc’s Current Ratio is 2.47. Further, the Quick Ratio stands at 2.88, while the Cash Ratio is 2.37.
Transactions by insiders
Recent insider trading involved Bachleda Mark, Chief Commercial Officer, that happened on Mar 16 when 11000.0 shares were purchased. Chief Financial Officer, Degnan Chris completed a deal on Mar 13 to buy 10000.0 shares. Meanwhile, President and CEO Sorensen Mel bought 100000.0 shares on Mar 10.